CoChat

Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases

Open access
Felice, C., Lewis, A., Armuzzi, A., Lindsay, J. O., Silver, A. · 2015 · Alimentary Pharmacology & Therapeutics
Cited by 120

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Summary: Background: A link between histone deacetylases (HDAC s) and intestinal inflammation has been established. HDAC inhibitors that target gut‐selective inflammatory pathways represent a potential new therapeutic strategy in patients with refractory inflammatory bowel diseases (IBD). Aims: To review the use of selective HDAC inhibitors to treat gut inflammation and to highlight potential improvements in selectivity/sensitivity by additional targeting of HDAC‐regulating micro RNA s (mi RNA s). Methods: Original articles and reviews have been identified using PubMed search terms: ‘histone deacetylase’, ‘HDAC inhibitor’, ‘inflammatory bowel disease’, ‘gut inflammation,’ and ‘micro RNA and HDAC’. Results: The use of butyrate in distal colitis provided the first evidence that inhibition of HDAC s decreases intestinal inflammation in IBD. HDAC inhibitors, such as valproic acid, vorinostat and givinostat, reduce inflammation and tissue damage in experimental murine colitis. Potential mechanisms of action for HDAC inhibitors include increased apoptosis, reduction of pro‐inflammatory cytokine release, regulation of transcription factors and modulation of HDAC‐regulatory mi RNA s. HDAC 2, HDAC 3, HDAC 6, HDAC 9 and HDAC 10 isoforms seem to be specifically involved in chronic intestinal inflammation, justifying the use of selective inhibitors as new therapeutic strategies in IBD. Controlling mi RNA s for these isoforms can be identified. Conclusions: The pro‐inflammatory influence of HDAC s in the gut has been confirmed, but mostly in murine studies. Considerably more human data are required to permit development of selective HDAC inhibitors for IBD treatment. Inhibition of key HDAC isoforms in combination with modulation of HDAC‐regulatory mi RNA s has potential as a novel therapeutic approach.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/apt.13008

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

Metadata

Authors
Felice, C., Lewis, A., Armuzzi, A., Lindsay, J. O., & Silver, A.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2014-11-04
Volume
41
Issue
1
Pages
26-38
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2028861852
Cited by
120
References
14
FWCI
3.89
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.